Contact information
Colleges
Gareth Purvis
BSs (Hons), MRes, PhD
Postdoctoral Researcher and Pre-Clinical (Non-Stipendiary) Lecturer
I completed my undergraduate degree in Biology at the University of York where I was awarded the Head of Department's Award. Following my bachelor's degree I was awarded a British Heart Foundation 4-year MRes/PhD studentship at Queen Mary University of London. I completed my PhD in the lab of Professor Christoph Thiemermann and Dr Egle Solito at the William Harvey Research Institute investigating the role of AnnexinA1 in the pathophysiology of diabetes.
Following completion of my PhD I moved to the University of Oxford where I worked in the lab of Professor David R Greaves within the Dunn School of Pathology on a British Heart Foundation funded program grant. My main research focus was to understand at a single cell level how monocytes are recruited and re-programmed to undergo monocyte to macrophage differentiation at sites of inflammation in disease relevant in vitro and in vivo models.
My current research focus is translational research as part of the Novo Nordisk Foundation funded MeRAID consortium; working with Prof Keith Channon we to better understand how metabolites alter cellular functions in diabetes and cardiovascular disease at an epigenetic level. I also have a long standing interesting into the role of Bruton's Tyrosine Kinase (BTK) and how this signalling hub can regulate monocyte and macrophage activation state through the regulation of cellular metabolism.
Key publications
-
OxPhos in adipose tissue macrophages regulated by BTK enhances their M2-like phenotype and confers a systemic immunometabolic benefit in obesity.
Purvis GSD. et al, (2024), Diabetes
-
A Human CD68 Promoter-Driven Inducible Cre-Recombinase Mouse Line Allows Specific Targeting of Tissue Resident Macrophages.
Rumianek AN. et al, (2022), Front Immunol, 13
-
Bruton's tyrosine kinase (BTK) regulates myeloid cell recruitment during acute inflammation.
Purvis GSD. et al, (2021), Br J Pharmacol
-
Annexin A1 attenuates microvascular complications through restoration of Akt signalling in a murine model of type 1 diabetes.
Purvis GSD. et al, (2018), Diabetologia, 61, 482 - 495
Recent publications
-
Drug repurposing screen identifies novel anti-inflammatory activity of sunitinib in macrophages.
Chaffey LE. et al, (2024), Eur J Pharmacol
-
OxPhos in adipose tissue macrophages regulated by BTK enhances their M2-like phenotype and confers a systemic immunometabolic benefit in obesity.
Purvis GSD. et al, (2024), Diabetes
-
Multityrosine kinase inhibitor sunitinib has anti-inflammatory activity in macrophages mediated via inhibition of NF-κB
Chaffey L. et al, (2023), BRITISH JOURNAL OF PHARMACOLOGY, 180, 536 - 537
-
OxPhos in adipose tissue macrophages regulated by BTK enhances their M2-like phenotype and confers a systemic immunometabolic benefit in obesity
Purvis G. et al, (2023)
-
A Human CD68 Promoter-Driven Inducible Cre-Recombinase Mouse Line Allows Specific Targeting of Tissue Resident Macrophages.
Rumianek AN. et al, (2022), Front Immunol, 13
-
Impact of metabolic disorders on the structural, functional, and immunological integrity of the blood-brain barrier: Therapeutic avenues.
Sheikh MH. et al, (2022), FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 36
-
Bruton's tyrosine kinase (BTK) regulates myeloid cell recruitment during acute inflammation.
Purvis GSD. et al, (2021), Br J Pharmacol
-
A novel hCD68 CreERT(2) mouse strain for macrophage targeting in vivo
Rumianek A. et al, (2021), BRITISH JOURNAL OF PHARMACOLOGY, 178, 4949 - 4949